With over 25 years of international experience in the pharmaceutical industry, Yves Decadt spent nearly 20 years at Johnson & Johnson in the international business development department, responsible for licensing and contract negotiations, with particular expertise in the Asia region. He has also held several senior management positions at leading biopharma and medtech companies.

Since August 2025, he has been working with the Poxel teams on a consultancy basis, notably leading an in-depth strategic review of the Company’s asset portfolio, which formed the basis for the proposed recovery plan presented to creditors and the Court. It was also under his leadership that the Company finalised the sale of PXL770 to Scynexis, a strategic transaction enabling the monetisation of this asset whilst freeing up the resources necessary for the continued development of Poxel’s priority assets.

Yves Decadt holds degrees in bioengineering and industrial management from the University of Ghent (Vlerick School), as well as in pharmacology and pharmaceutical medicine from the Université Libre de Bruxelles. He also holds the Board Director certification from Duke University.